XML 59 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Out-Licensing Agreements - Deferred Revenue (Details)
$ in Thousands
9 Months Ended 21 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
Collaborative agreements    
Long-term Deferred Revenue $ 14,198 $ 14,198
Additions 26,290  
Balance at end of period 26,290 26,290
Territory License - Rilonacept | Huadong rilonacept    
Collaborative agreements    
Long-term Deferred Revenue 12,000 12,000
Additions 12,000  
Balance at end of period 12,000 12,000
Territory License - Rilonacept | Huadong rilonacept | License and collaboration revenue    
Collaborative agreements    
Revenue recognized   0
Worldwide License - Vixarelimab | Genentech    
Collaborative agreements    
Additions 14,290  
Balance at end of period $ 14,290 $ 14,290